Antibodies against PDGFRα to inhibit tumor growth
AssigneeImClone LLC
InventorsNick Loizos, Jim Huber
Life of this patent
Estimating the term…
Abstract
The invention provides antibodies that bind to human PDGFRα and neutralize activation of the receptor. The invention further provides methods for neutralizing activation of PDGFRα and methods of treating a mammal with a neoplastic disease using the antibodies alone or in combination with other agents.
Claims3
A method of inhibiting growth of a primary tumor or a metastatic tumor in a patient in need thereof by administering to the patient an effective amount of an antibody or an antibody fragment thereof specific for human PDGFR alpha and comprising SSSYY (SEQ ID NO:2) at CDRH1;
- SFFYTGSTYYNPSLRS (SEQ ID NO:4) at CDRH2;
- QSTYYYGSGNYYGWFDR (SEQ ID NO:6) at CDRH3;
- RASQSVSSYLA (SEQ ID NO:10) at CDRL1;
- DASNRAT (SEQ ID NO:12) at CDRL2;
- and QQRSNWPPA (SEQ ID NO:14) at CDRL3, wherein the tumor is selected from the group consisting of a leiomyosarcoma and a glioblastoma.
A method of inhibiting growth of a primary tumor or a metastatic tumor in a patient in need thereof by administering to the patient an effective amount of an antibody or an antibody fragment thereof specific for human PDGFR alpha and comprising a heavy chain variable region having the amino acid sequence:
- (SEQ ID NO:
- 8)
- QLQLQESGPGLVKPSETLSLTCTVSGGSINSSSYYWGWLRQSPGKGLEW
- IGSFFYTGSTYYNPSLRSRLTISVDTSKNQFSLMLSSVTAADTAVYYCA
- RQSTYYYGSGNYYGWFDRWDQGTLVTVSS
- and a light chain variable region having the amino acid sequence:
- (SEQ ID NO:
- 16)
- EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIY
- DASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPAF
- GQGTKVEIK,
- wherein the tumor is selected from the group consisting of a leiomyosarcoma, and a glioblastoma.
Dependencies are inferred from the claim text.